Iterum Therapeutics plc (ITRM) Institutional Ownership

Ownership Summary

The institutional landscape for Iterum Therapeutics plc (NASDAQ:ITRM) includes 8 filers as of the latest reporting cycle ending December 2025.

• These investors collectively held 2.2% of the company's total shares outstanding in December 2025, down from 3.5% in September 2025.
• On a quarter-over-quarter basis, institutional holdings shifted by 185.15%, with a year-over-year a decrease of 66.67% in the count of filers.
• Among the 8 institutional holders of Iterum Therapeutics, 4 added to their stakes while 1 trimmed their positions and 3 held steady.
• This class of investors increased its holdings in Iterum Therapeutics to 843.61K shares for the 13F-cycle ending December 2025, up by 547.76K shares quarter on quarter, and down 386.87K shares year over year.
• Apollon Financial, LLC continues to be the largest institutional holder of Iterum Therapeutics as of December 31, 2025, with a position of 630.25K shares, representing 1.66% of the company's outstanding stock.
• Among the most significant buyers of Iterum Therapeutics during December 2025 were Apollon Financial, LLC (380.00K), UBS Group AG (111.32K), Krilogy Financial LLC (40.00K), Ground Swell Capital, LLC (20.48K).
• Leading sellers of Iterum Therapeutics stock in December 2025 included SG Americas Securities, LLC (4.04K).
• The top 8 institutional holders of Iterum Therapeutics for the quarter ending December 2025 included Apollon Financial, LLC (630.25K), UBS Group AG (119.95K), Krilogy Financial LLC (40.00K), Ground Swell Capital, LLC (20.48K), Sanctuary Advisors, LLC (20.00K), SG Americas Securities, LLC (12.78K), Activest Wealth Management (133), SBI Securities Co., Ltd. (16).